InnoCare Presents Orelabrutinib Study Results with 89.5% ORR at ASH 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Should l Buy 09969?
Source: Globenewswire
- Remarkable Efficacy: At the 2025 ASH Annual Meeting, InnoCare's BTK inhibitor orelabrutinib demonstrated significant efficacy across multiple lymphoma studies, particularly in newly diagnosed primary central nervous system lymphoma, achieving an objective response rate (ORR) of 89.5%, providing new hope for patients.
- Good Safety Profile: The combination of orelabrutinib with rituximab and high-dose methotrexate in newly diagnosed PCNSL patients showed good tolerability, while early biomarker monitoring aids in real-time risk stratification, optimizing treatment strategies.
- Promising Clinical Applications: In preliminary studies for marginal zone lymphoma, the combination of orelabrutinib with obinutuzumab achieved an ORR of 96.0%, indicating its potential as a chemotherapy-free first-line treatment option, which could transform existing treatment paradigms.
- Enhanced Market Competitiveness: By showcasing over 20 studies at the ASH meeting, InnoCare not only elevated its visibility in the biopharmaceutical sector but may also attract more investor interest, thereby strengthening its market competitiveness and future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy 09969?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on 09969
Wall Street analysts forecast 09969 stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 13.930
Low
Averages
High
Current: 13.930
Low
Averages
High
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
INNOCARE Anticipates First-Time NP of RMB633M Last Year, with Total Operating Revenue Projected to Increase by 134%
Company Performance: INNOCARE (09969.HK) is expected to achieve a total operating revenue of approximately RMB2.365 billion for the year ending 31 December 2025, reflecting a year-on-year increase of about 134%.
Stock Movement: The company's stock price has decreased by 0.050, or 0.428%.
Short Selling Activity: There has been short selling activity amounting to $5.86 million, with a short selling ratio of 14.112%.
Market Outlook: The significant revenue growth indicates a positive market outlook for INNOCARE in the upcoming year.
See More
InnoCare Pharma Receives IND Approval for Phase II Trial of ICP-488 in CLE
- New Drug Development Progress: InnoCare Pharma has received approval from the China National Medical Products Administration to initiate a Phase II clinical trial for ICP-488 targeting cutaneous lupus erythematosus, marking a significant advancement in the company's research on autoimmune diseases and addressing urgent market needs for new therapies.
- Drug Characteristics Advantage: ICP-488 is an oral, selective TYK2 inhibitor that blocks the signaling of IL-23, IL-12, and other inflammatory cytokines, offering a more convenient treatment option compared to injectable biologics, which may attract a larger patient base.
- Clinical Trial Success Potential: Following favorable efficacy and safety results in the Phase II trial for psoriasis, with Phase III enrollment nearing completion, the likelihood of successful market entry for ICP-488 has significantly increased, further solidifying InnoCare's position in the biopharmaceutical market.
- Market Demand Alignment: As a common autoimmune disease, the demand for effective treatment options for cutaneous lupus erythematosus is rising, and InnoCare's drug development efforts will help fill this market gap, driving business growth in China and globally.
See More
InnoCare Pharma Receives IND Approval for Phase II Trial of ICP-488 for CLE Treatment
- Clinical Trial Approval: InnoCare Pharma has received approval from the China National Medical Products Administration to initiate a Phase II clinical trial for ICP-488 targeting cutaneous lupus erythematosus, marking a significant advancement in the company's development in the autoimmune disease sector.
- Drug Characteristics: ICP-488 is an oral, selective TYK2 allosteric inhibitor that blocks the signal transduction of IL-23, IL-12, and other inflammatory cytokines, demonstrating potential therapeutic effects for autoimmune and inflammatory diseases, which may offer patients a more convenient treatment option compared to injectable biologics.
- Market Demand: Cutaneous lupus erythematosus is a common autoimmune disease, with some patients potentially progressing to systemic lupus erythematosus, indicating that the development of ICP-488 will address unmet medical needs in this area, presenting significant market potential.
- Strategic Development: The co-founder and CEO of InnoCare stated that ICP-488 has shown favorable efficacy and safety in the Phase II trial for psoriasis, with enrollment for the Phase III study nearing completion, reflecting the company's commitment to accelerating clinical development to meet market demands.
See More
Zenas Acquires Global Rights for Orelabrutinib, Enhancing Multiple Sclerosis Treatment Potential
- Clinical Trial Success: In a Phase 2b trial for Systemic Lupus Erythematosus (SLE) involving 187 patients, the orelabrutinib 75 mg QD group achieved a 57.1% SRI-4 response rate at week 48, significantly surpassing the placebo group's 34.4%, which not only met the primary endpoint but also lays a strong foundation for future market introduction.
- Acquisition of Global Rights: Zenas secured exclusive global rights to develop, manufacture, and commercialize orelabrutinib outside Greater China and Southeast Asia through a 2025 licensing agreement with InnoCare, significantly enhancing its competitive edge in the Multiple Sclerosis market.
- Good Safety Profile: Orelabrutinib demonstrated good tolerability in clinical trials, with a safety profile consistent with BTK inhibition mechanisms, providing confidence for future clinical applications and potentially accelerating regulatory approval processes.
- Strategic Investment Outlook: Zenas also acquired development rights for ZB021 and ZB022, which will further enrich its product pipeline, strengthening its market position in autoimmune diseases and is expected to drive future revenue growth.
See More
Zenas Acquires Global Rights for Orelabrutinib, Enhancing Multiple Sclerosis Treatment Potential
- Clinical Trial Success: In a Phase 2b clinical trial involving 187 patients with Systemic Lupus Erythematosus (SLE), the orelabrutinib 75 mg once-daily group achieved a 57.1% SLE Response Index-4 (SRI-4) response rate at week 48, significantly surpassing the placebo group's 34.4%, thereby not only meeting the primary endpoint but also laying the groundwork for subsequent Phase 3 trials.
- Acquisition of Global Rights: Zenas secured exclusive rights to develop, manufacture, and commercialize orelabrutinib for Multiple Sclerosis (MS) and non-oncology fields outside Greater China and Southeast Asia through a 2025 licensing agreement with InnoCare, significantly enhancing its competitive position in the global biopharmaceutical market.
- Good Safety Profile: The clinical trial demonstrated that orelabrutinib was well tolerated, with a safety profile consistent with the mechanism of action of BTK inhibition and the underlying biology of SLE, providing confidence for future market promotion.
- Strategic Investment Outlook: Zenas is advancing a Phase 3 trial for Primary Progressive Multiple Sclerosis, expected to initiate in Q1 2026, which will further solidify its leadership position in the autoimmune disease sector.
See More
InnoCare's Orelabrutinib Phase IIb Trial Achieves Primary Endpoint in SLE Patients
- Clinical Trial Success: InnoCare's BTK inhibitor orelabrutinib met its primary endpoint in the Phase IIb trial for systemic lupus erythematosus (SLE), with the 75 mg group achieving a 57.1% SRI-4 response rate at 48 weeks, significantly higher than the 34.4% in the placebo group, demonstrating the drug's efficacy.
- Good Safety Profile: Among 187 patients, orelabrutinib exhibited a safety profile consistent with BTK inhibition, with no severe adverse reactions reported, indicating its good tolerability in SLE patients and enhancing its market prospects.
- Registration Trial Approved: InnoCare has received approval from the Center for Drug Evaluation to conduct a Phase III registrational trial for orelabrutinib, marking a significant step towards market introduction and expected to address the long-term treatment needs of SLE patients.
- Huge Market Potential: With approximately 8 million people suffering from SLE globally and around 1 million in China, the drug holds significant potential to meet the substantial unmet medical needs, particularly among young female patients.
See More
INNOCARE Anticipates First-Time NP of RMB633M Last Year, with Total Operating Revenue Projected to Increase by 134%
Company Performance: INNOCARE (09969.HK) is expected to achieve a total operating revenue of approximately RMB2.365 billion for the year ending 31 December 2025, reflecting a year-on-year increase of about 134%.
Stock Movement: The company's stock price has decreased by 0.050, or 0.428%.
Short Selling Activity: There has been short selling activity amounting to $5.86 million, with a short selling ratio of 14.112%.
Market Outlook: The significant revenue growth indicates a positive market outlook for INNOCARE in the upcoming year.
See More
InnoCare Pharma Receives IND Approval for Phase II Trial of ICP-488 in CLE
- New Drug Development Progress: InnoCare Pharma has received approval from the China National Medical Products Administration to initiate a Phase II clinical trial for ICP-488 targeting cutaneous lupus erythematosus, marking a significant advancement in the company's research on autoimmune diseases and addressing urgent market needs for new therapies.
- Drug Characteristics Advantage: ICP-488 is an oral, selective TYK2 inhibitor that blocks the signaling of IL-23, IL-12, and other inflammatory cytokines, offering a more convenient treatment option compared to injectable biologics, which may attract a larger patient base.
- Clinical Trial Success Potential: Following favorable efficacy and safety results in the Phase II trial for psoriasis, with Phase III enrollment nearing completion, the likelihood of successful market entry for ICP-488 has significantly increased, further solidifying InnoCare's position in the biopharmaceutical market.
- Market Demand Alignment: As a common autoimmune disease, the demand for effective treatment options for cutaneous lupus erythematosus is rising, and InnoCare's drug development efforts will help fill this market gap, driving business growth in China and globally.
See More
InnoCare Pharma Receives IND Approval for Phase II Trial of ICP-488 for CLE Treatment
- Clinical Trial Approval: InnoCare Pharma has received approval from the China National Medical Products Administration to initiate a Phase II clinical trial for ICP-488 targeting cutaneous lupus erythematosus, marking a significant advancement in the company's development in the autoimmune disease sector.
- Drug Characteristics: ICP-488 is an oral, selective TYK2 allosteric inhibitor that blocks the signal transduction of IL-23, IL-12, and other inflammatory cytokines, demonstrating potential therapeutic effects for autoimmune and inflammatory diseases, which may offer patients a more convenient treatment option compared to injectable biologics.
- Market Demand: Cutaneous lupus erythematosus is a common autoimmune disease, with some patients potentially progressing to systemic lupus erythematosus, indicating that the development of ICP-488 will address unmet medical needs in this area, presenting significant market potential.
- Strategic Development: The co-founder and CEO of InnoCare stated that ICP-488 has shown favorable efficacy and safety in the Phase II trial for psoriasis, with enrollment for the Phase III study nearing completion, reflecting the company's commitment to accelerating clinical development to meet market demands.
See More
Zenas Acquires Global Rights for Orelabrutinib, Enhancing Multiple Sclerosis Treatment Potential
- Clinical Trial Success: In a Phase 2b trial for Systemic Lupus Erythematosus (SLE) involving 187 patients, the orelabrutinib 75 mg QD group achieved a 57.1% SRI-4 response rate at week 48, significantly surpassing the placebo group's 34.4%, which not only met the primary endpoint but also lays a strong foundation for future market introduction.
- Acquisition of Global Rights: Zenas secured exclusive global rights to develop, manufacture, and commercialize orelabrutinib outside Greater China and Southeast Asia through a 2025 licensing agreement with InnoCare, significantly enhancing its competitive edge in the Multiple Sclerosis market.
- Good Safety Profile: Orelabrutinib demonstrated good tolerability in clinical trials, with a safety profile consistent with BTK inhibition mechanisms, providing confidence for future clinical applications and potentially accelerating regulatory approval processes.
- Strategic Investment Outlook: Zenas also acquired development rights for ZB021 and ZB022, which will further enrich its product pipeline, strengthening its market position in autoimmune diseases and is expected to drive future revenue growth.
See More
Zenas Acquires Global Rights for Orelabrutinib, Enhancing Multiple Sclerosis Treatment Potential
- Clinical Trial Success: In a Phase 2b clinical trial involving 187 patients with Systemic Lupus Erythematosus (SLE), the orelabrutinib 75 mg once-daily group achieved a 57.1% SLE Response Index-4 (SRI-4) response rate at week 48, significantly surpassing the placebo group's 34.4%, thereby not only meeting the primary endpoint but also laying the groundwork for subsequent Phase 3 trials.
- Acquisition of Global Rights: Zenas secured exclusive rights to develop, manufacture, and commercialize orelabrutinib for Multiple Sclerosis (MS) and non-oncology fields outside Greater China and Southeast Asia through a 2025 licensing agreement with InnoCare, significantly enhancing its competitive position in the global biopharmaceutical market.
- Good Safety Profile: The clinical trial demonstrated that orelabrutinib was well tolerated, with a safety profile consistent with the mechanism of action of BTK inhibition and the underlying biology of SLE, providing confidence for future market promotion.
- Strategic Investment Outlook: Zenas is advancing a Phase 3 trial for Primary Progressive Multiple Sclerosis, expected to initiate in Q1 2026, which will further solidify its leadership position in the autoimmune disease sector.
See More
InnoCare's Orelabrutinib Phase IIb Trial Achieves Primary Endpoint in SLE Patients
- Clinical Trial Success: InnoCare's BTK inhibitor orelabrutinib met its primary endpoint in the Phase IIb trial for systemic lupus erythematosus (SLE), with the 75 mg group achieving a 57.1% SRI-4 response rate at 48 weeks, significantly higher than the 34.4% in the placebo group, demonstrating the drug's efficacy.
- Good Safety Profile: Among 187 patients, orelabrutinib exhibited a safety profile consistent with BTK inhibition, with no severe adverse reactions reported, indicating its good tolerability in SLE patients and enhancing its market prospects.
- Registration Trial Approved: InnoCare has received approval from the Center for Drug Evaluation to conduct a Phase III registrational trial for orelabrutinib, marking a significant step towards market introduction and expected to address the long-term treatment needs of SLE patients.
- Huge Market Potential: With approximately 8 million people suffering from SLE globally and around 1 million in China, the drug holds significant potential to meet the substantial unmet medical needs, particularly among young female patients.
See More
